Major AEs included myelosuppression (74.4%), gastrointestinal reactions (89.7%), and pigmentation (53.8%); however, they were generally mild and no treatment-related deaths occurred. Anemia (71.8%) was common, and thrombocytopenia was rare (0%). Anorexia (64.1%) was common, and diarrhea was not. Grade 3 AEs occurred in 13 patients (33.3%), and grade 4 AEs occurred in 1 of them (2.6%). Each type of the grade 3–4 AEs occurred in only 1–3 patients, with gastrointestinal reactions in 15.4% and myelosuppression in 10.3% (Table 2).Table 2Adverse eventsAdverse eventsS-1 plus LV (N = 39)Grade 1 (%)Grade 2 (%)Grade 3 (%)Grade 4 (%)All grade (%)Leukopenia6 (15.4)7 (17.9)1 (2.6)014 (35.9)Neutropenia4 (10.3)7 (17.9)1 (2.6)1 (2.6)12 (33.3)Anemia17 (43.6)10 (25.6)1 (2.6)028 (71.8)Thrombocytopenia00000Asthenia9 (23.1)0009 (23.1)Anorexia19 (48.7)5 (12.8)1 (2.6)025 (64.1)Nausea11 (28.2)1 (2.6)0012 (30.8)Vomiting3 (7.7)2 (5.1)1 (2.6)06 (15.4)Diarrhea9 (23.1)1 (2.6)1 (2.6)011 (28.2)Abdominal pain5 (12.8)4 (10.3)2 (5.1)011 (28.2)Skin rash5 (12.8)0005 (12.8)Hand–foot syndrome3 (7.7)1 (2.6)004 (10.3)Pigmentation16 (41.0)5 (12.8)0021 (53.8)Stomatitis6 (15.4)3 (7.7)1 (2.6)010 (25.6)Blurred vision4 (10.3)0004 (10.3)Lacrimation increased4 (10.3)0004 (10.3)Tinnitus1 (2.6)0001 (2.6)ALT elevation4 (10.3)2 (5.1)3 (7.7)09 (23.1)AST elevation4 (10.3)1 (2.6)2 (5.1)07 (17.9)Hypoalbuminemia12 (30.8)2 (5.1)0014 (35.9)Proteinuria1 (2.6)0001 (2.6)